I am excited to announce Diabetes, Obesity and Metabolism, an international, peer-reviewed journal, recently published the results of the continuation phase of our OpT2mise study, which could redefine the standard of care and expand access to insulin pump therapy for the growing population of insulin-dependent people with type 2 diabetes with poor glucose control.
Our OpT2mise study is the largest randomized controlled trial to compare the efficacy and safety of insulin pump therapy versus multiple daily injections (MDI). The study demonstrated MiniMed insulin pumps provide significant, sustainable and reproducible improvements in glucose control for people with type 2 diabetes in comparison to MDI.
During the first part of the study, 331 people with poorly controlled type 2 diabetes –ranging in age from 30 to 75 years – were randomized to be treated with pump therapy or MDI. In July 2014, The Lancet, one of the world’s most prestigious medical journals, published six-month data which demonstrated superior clinical outcomes for people with type 2 diabetes on insulin pump therapy, as compared to patients who administered MDI.
At the end of the first phase of the study, the group that remained on MDI was also switched over to MiniMed pump therapy. After six months of pump therapy, this group experienced a similar reduction in A1C as the original randomized insulin pump group. More specifically, pump therapy consistently drove a 1.2% reduction in A1C levels compared to the baselines at the 12-month mark. What’s even more striking is that this was done while utilizing 19% less insulin!
To put things in perspective, a 1% reduction in A1C is associated with a 40% reduction in the risk of long-term complications from diabetes such as eye disease, heart attacks, nerve damage, blood flow, and kidney disease.(1, 2)
The results of the OpT2mise trial prove insulin-dependent people with type 2 diabetes benefit from improved clinical outcomes by switching to pump therapy. Having solid clinical evidence of this not only helps guide physician recommendations, but also demonstrates the value of the technology to payors, helping with insurance coverage and access to supplies. This is a significant milestone in our efforts to improve access to insulin pumps for the millions people around the world with type 2 diabetes who require insulin.
Learn more about the OpT2mise 12-month study data.
IMPORTANT SAFETY INFORMATION
- Medtronic Diabetes insulin infusion pumps, continuous glucose monitoring systems and associated components are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks associated with the use of these systems.
- Successful operation of the insulin infusion pumps and/or continuous glucose monitoring systems requires adequate vision and hearing to recognize alerts and alarms.
Medtronic Diabetes Insulin Infusion Pumps
- Insulin pump therapy is not recommended for individuals who are unable or unwilling to perform a minimum of four blood glucose tests per day.
- Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately.
Please visit MedtronicDiabetes.com/isi for more details.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
Tags: clinical trial
, insulin pump
, multiple daily injections
, type 2 diabetes